199 related articles for article (PubMed ID: 23183529)
1. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis.
Bruno S; Vierling JM; Esteban R; Nyberg LM; Tanno H; Goodman Z; Poordad F; Bacon B; Gottesdiener K; Pedicone LD; Albrecht JK; Brass CA; Thompson S; Burroughs MH
J Hepatol; 2013 Mar; 58(3):479-87. PubMed ID: 23183529
[TBL] [Abstract][Full Text] [Related]
2. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.
Vierling JM; Davis M; Flamm S; Gordon SC; Lawitz E; Yoshida EM; Galati J; Luketic V; McCone J; Jacobson I; Marcellin P; Muir AJ; Poordad F; Pedicone LD; Albrecht J; Brass C; Howe AY; Colvard LY; Helmond FA; Deng W; Treitel M; Wahl J; Bronowicki JP
J Hepatol; 2014 Apr; 60(4):748-56. PubMed ID: 24362076
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials.
Vierling JM; Zeuzem S; Poordad F; Bronowicki JP; Manns MP; Bacon BR; Esteban R; Flamm SL; Kwo PY; Pedicone LD; Deng W; Dutko FJ; DiNubile MJ; Koury KJ; Helmond FA; Wahl J; Bruno S
J Hepatol; 2014 Aug; 61(2):200-9. PubMed ID: 24747798
[TBL] [Abstract][Full Text] [Related]
4. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.
Flamm SL; Lawitz E; Jacobson I; Bourlière M; Hezode C; Vierling JM; Bacon BR; Niederau C; Sherman M; Goteti V; Sings HL; Barnard RO; Howe JA; Pedicone LD; Burroughs MH; Brass CA; Albrecht JK; Poordad F
Clin Gastroenterol Hepatol; 2013 Jan; 11(1):81-87.e4; quiz e5. PubMed ID: 23064222
[TBL] [Abstract][Full Text] [Related]
5. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
Sulkowski M; Pol S; Mallolas J; Fainboim H; Cooper C; Slim J; Rivero A; Mak C; Thompson S; Howe AY; Wenning L; Sklar P; Wahl J; Greaves W;
Lancet Infect Dis; 2013 Jul; 13(7):597-605. PubMed ID: 23768747
[TBL] [Abstract][Full Text] [Related]
6. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.
Jacobson IM; Marcellin P; Zeuzem S; Sulkowski MS; Esteban R; Poordad F; Bruno S; Burroughs MH; Pedicone LD; Boparai N; Deng W; DiNubile MJ; Gottesdiener KM; Brass CA; Albrecht JK; Bronowicki JP
Hepatology; 2012 Aug; 56(2):567-75. PubMed ID: 22619063
[TBL] [Abstract][Full Text] [Related]
7. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.
Sulkowski MS; Poordad F; Manns MP; Bronowicki JP; Rajender Reddy K; Harrison SA; Afdhal NH; Sings HL; Pedicone LD; Koury KJ; Sniukiene V; Burroughs MH; Albrecht JK; Brass CA; Jacobson IM;
Hepatology; 2013 Mar; 57(3):974-84. PubMed ID: 23081753
[TBL] [Abstract][Full Text] [Related]
8. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
[TBL] [Abstract][Full Text] [Related]
9. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.
Ferrante SA; Chhatwal J; Brass CA; El Khoury AC; Poordad F; Bronowicki JP; Elbasha EH
BMC Infect Dis; 2013 Apr; 13():190. PubMed ID: 23621902
[TBL] [Abstract][Full Text] [Related]
10. Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan.
Hsieh MH; Yeh ML; Su TH; Liu TW; Huang CF; Huang CI; Wang SC; Huang JF; Dai CY; Kao JH; Chuang WL; Chen PJ; Liu CJ; Yu ML
J Formos Med Assoc; 2018 Jun; 117(6):497-504. PubMed ID: 28694000
[TBL] [Abstract][Full Text] [Related]
11. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.
Poizot-Martin I; Bellissant E; Garraffo R; Colson P; Piroth L; Solas C; Renault A; Bourlière M; Halfon P; Ghosn J; Alric L; Naqvi A; Carrieri P; Molina JM;
HIV Clin Trials; 2016 Mar; 17(2):63-71. PubMed ID: 27077673
[TBL] [Abstract][Full Text] [Related]
12. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.
Manns MP; Vierling JM; Bacon BR; Bruno S; Shibolet O; Baruch Y; Marcellin P; Caro L; Howe AY; Fandozzi C; Gress J; Gilbert CL; Shaw PM; Cooreman MP; Robertson MN; Hwang P; Dutko FJ; Wahl J; Mobashery N
Gastroenterology; 2014 Aug; 147(2):366-76.e6. PubMed ID: 24727022
[TBL] [Abstract][Full Text] [Related]
13. Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program.
Bruno S; Bollani S; Zignego AL; Pascasio JM; Magni C; Ciancio A; Caremani M; Mangia A; Marenco S; Piovesan S; Chemello L; Babudieri S; Moretti A; Gea F; Colletta C; Perez-Alvarez R; Forns X; Larrubia JR; Arenas J; Crespo J; Calvaruso V; Ceccherini Silberstein F; Maisonneuve P; Craxì A; Calleja JL;
J Viral Hepat; 2015 May; 22(5):469-80. PubMed ID: 25311757
[TBL] [Abstract][Full Text] [Related]
14. Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients.
Yang CC; Tsai WL; Su WW; Huang CF; Cheng PN; Lo CC; Tseng KC; Mo LR; Wang CH; Hsu SJ; Lai HC; Su CW; Liu CJ; Peng CY; Yu ML
PLoS One; 2015; 10(9):e0137852. PubMed ID: 26368130
[TBL] [Abstract][Full Text] [Related]
15. Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.
Gordon SC; Reddy KR; Jacobson IM; Poordad F; Bronowicki JP; Bacon B; Buti M; Hu KQ; Pedicone LD; Burroughs M; Brass CA; Albrecht JK; Lawitz EJ
J Clin Gastroenterol; 2014; 48(5):435-43. PubMed ID: 24177376
[TBL] [Abstract][Full Text] [Related]
16. Boceprevir: a protease inhibitor for the treatment of hepatitis C.
Chang MH; Gordon LA; Fung HB
Clin Ther; 2012 Oct; 34(10):2021-38. PubMed ID: 22975763
[TBL] [Abstract][Full Text] [Related]
17. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
Marcellin P; Cooper C; Balart L; Larrey D; Box T; Yoshida E; Lawitz E; Buggisch P; Ferenci P; Weltman M; Labriola-Tompkins E; Le Pogam S; Nájera I; Thomas D; Hooper G; Shulman NS; Zhang Y; Navarro MT; Lim CY; Brunda M; Terrault NA; Yetzer ES
Gastroenterology; 2013 Oct; 145(4):790-800.e3. PubMed ID: 23811112
[TBL] [Abstract][Full Text] [Related]
18. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation.
Pungpapong S; Aqel BA; Koning L; Murphy JL; Henry TM; Ryland KL; Yataco ML; Satyanarayana R; Rosser BG; Vargas HE; Charlton MR; Keaveny AP
Liver Transpl; 2013 Jul; 19(7):690-700. PubMed ID: 23696372
[TBL] [Abstract][Full Text] [Related]
19. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
20. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
Dore GJ; Lawitz E; Hézode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Tran A; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey D; Pol S; Harley H; George J; Fung SK; de Lédinghen V; Hagens P; McPhee F; Hernandez D; Cohen D; Cooney E; Noviello S; Hughes EA
Gastroenterology; 2015 Feb; 148(2):355-366.e1. PubMed ID: 25311593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
